TargetMol

4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (His)

Product Code:
 
TAR-TMPY-01743
Product Group:
 
Recombinant Proteins
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TMPY-01743-100ug100ug£249.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPY-01743-200ug200ug£417.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TMPY-01743-500ug500ug£906.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 18.8 kDa and the accession number is Q07011.
Molecular Weight:
18.8 kDa (predicted)
Purity:
SDS-PAGE: 92.3%; SEC-HPLC: 94.4%

References

1.Sica G,et al.(1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9. 2.Nam KO,et al.(2005)?The therapeutic potential of 4-1BB (CD137) in cancer.?Curr Cancer Drug Targets. 5(5): 357-63. 3.Wang Q,et al.(2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200. 4.Melero I,et al.(2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90. 5.Thum E,et al.(2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.